Answers are grounded in this paper and cite their sources.
Systematic review assesses I-PRF therapy effectiveness in temporomandibular joint disorders, suggesting positive outcomes.
OBJECTIVE: Temporomandibular joint internal derangement with reduction commonly causes pain, joint clicking, and limited jaw movement. Injectable platelet-rich fibrin (I-PRF), an autologous concentrate containing growth factors, has emerged as a potential regenerative treatment. METHODS: This systematic review assessed the effectiveness of intra-articular I-PRF as a sole therapy for temporomandibular disorders (TMD). A literature search of PubMed, Scopus, Embase, and Web of Science (2015-2025) identified five eligible studies following PRISMA guidelines. RESULTS AND DISCUSSION: Included studies reported reduced pain, improved mouth opening, and decreased joint sounds after I-PRF therapy, without significant adverse effects. However, variations in study design and treatment protocols were noted. CONCLUSION: Overall, current evidence indicates that I-PRF may improve symptoms and jaw function as a minimally invasive conservative treatment for TMD. Nonetheless, the evidence remains limited due to methodological heterogeneity and the predominance of non-randomized studies, highlighting the need for further high-quality randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Nursanti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: